Protein kinase C-α: A novel target for the therapy of androgen-independent prostate cancer? (Review-hypothesis)

Oncology Reports

Volumn 5, Issue 2, 1998, Pages 305-309

  O'Brian, Catherine A ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Androgen independent; Cancer therapeutics; PKC ; Prostate cancer; Protein kinase C isozymes

Indexed keywords

ANDROGEN; ISOENZYME; PROTEIN KINASE C;

CANCER GROWTH; CELL SURVIVAL; ENZYME REGULATION; HORMONE ACTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ANDROGENS; ANIMALS; APOPTOSIS; ENZYME INHIBITORS; HUMANS; ISOENZYMES; MALE; PHORBOL ESTERS; PROSTATIC NEOPLASMS; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; TUMOR CELLS, CULTURED;

EID: 0031887309     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Lee C, Shevrin DH and Kozlowski JM: In vivo and in vitro approaches to study metastasis in human prostate cancer. Cancer Metastasis Rev 12: 21-28, 1993.
2. Konety BR and Getzenberg RH: Novel therapies for advanced prostate cancer. Semin Urol Oncol 15: 33-42, 1997.
3. Ismail M and Gomella LG: Current treatment of advanced prostate cancer. Techs Urol 3: 16-24, 1997.
4. Kirby RS: Recent advances in the medical management of prostate cancer. Br J Clin Pract 50: 88-93, 1996.
5. Blobe GC, Stribling S, Obeid LM and Hannun YA: Protein kinase C isoenzymes: Regulation and function. Cancer Surv 27: 213-248, 1996.
6. Kuo JF (ed.): Protein Kinase C. Oxford Univ Press, New York, 1994.
7. O'Brian CA and Ward NE: Biology of the protein kinase C family. Cancer Metastasis Rev 8: 199-214, 1989.
8. Ways DK, Kukoly CA, de Vente J, Hooker JL, Bryant WO, Posekany KJ, Fletcher DJ, Cook PP and Parker PJ: MCF7 breast cancer cells transfected with protein kinase C-α exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest 95: 1906-1915, 1995.
9. Connolly JM and Rose DP: Expression of the invasive phenotype by MCF7 human breast cancer cells transfected to overexpress protein kinase C-α or the erbB2 proto-oncogene. Int J Oncol 10: 71-76, 1997.
10. Liu B, Maher RJ, Hannun YA, Porter AT and Honn KV: 12(S)-HETE enhancement of prostate tumor cell invasion: Selective role of PKC-α. J Natl Cancer Inst 86: 1145-1151, 1994.
11. Fine RL, Patel J and Chabner BA: Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 85: 582-586, 1988.
12. Blobe GC, Sachs CW, Khan WA, Fabbro D, Stabel S, Wetsel WC, Obeid LM, Fine RL and Hannun YA: Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug resistant MCF-7 cells. J Biol Chem 268: 658-664, 1993.
13. Gupta KP, Ward NE, Gravitt KR, Bergman PJ and O'Brian CA; Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-α pseudosubstrate peptide. J Biol Chem 271: 2102-2111, 1996.
14. Powell CT, Fair WR and Heston WDW: Differential expression of protein kinase C isozyme messenger RNAs in Dunning R-3327 rat prostatic tumors. Cell Growth Diff 5: 143-149, 1994.
15. Battistone MJ, Padilla GM and Petrow V: 1-Dehydromelengestrol acetate inhibits the growth and protein kinase C activity of androgen-independent Dunning rat prostatic tumors. Cancer Chemother Pharmacol 31: 407-11, 1993.
16. Powell CT, Brittis NJ, Stec D, Hug H, Heston WDW and Fair WR: Persistent membrane translocation of protein kinase C-α during 12-0-tetradecanoylphorbol-13-acetate-induced apoptosis of LNCaP human prostate cancer cells. Cell Growth Differ 7: 419-428, 1996.
17. Timar J, Raso E, Fazakas ZS, Silletti S and Honn KV: Multiple use of a signal transduction pathway in tumor cell invasion. Anticancer Res 16: 3299-3306, 1996.
18. Krongard A and Bai G: C-fos promoter insensitivity to phorbol ester and possible role of protein kinase C in androgen-independent cancer cells. Cancer Res 54: 6073-6077, 1994.
19. Fisch TM, Prywes R and Roeder RG: C-fos sequence necessary for basal expression and induction by epidermal growth factor, 12-0-tetradecanoyl phorbol-13-acetate and the calcium ionophore. Mol Cell Biol 7: 3490-3502, 1987.
20. Day ML, Zhao X, Wu S, Swanson PE and Humphrey PA: Phorbol ester-induced apoptosis is accompanied by NGF1-A and c-fos activation in androgen-sensitive prostate cancer cells. Cell Growth Differ 5: 735-741, 1994.
21. Young CYF, Murtha PE and Zhang J: Tumor-promoting phorbol ester-induced cell death and gene expression in a human prostate adenocarcinoma cell line. Oncol Res 6: 203-210, 1994.
22. Zhao X, Gschwend JE, Powell CT, Foster RG, Day KC and Day ML: Retinoblastoma protein-dependent growth signal conflict and caspase activity are required for protein kinase C-signaled apoptosis of prostate epithelial cells. J Biol Chem 272: 22751-22757, 1997.
23. Isaacs WB, Carter BS and Ewing CM: Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51: 4716-4720, 1991.
24. Herbert JM, Augereau JM, Gleye J and Maffrand JP: Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 172: 993-999, 1990.
25. Konno S, Hsieh TC, Wu JM, Chen Y, Chiao JW and Mallouh C: Growth control of human prostatic cancer cells by the phorbol ester TPA: Possible involvement of protein kinases. Anticancer Res 16: 1843-1850, 1996.
26. Lopez-Lopez R, Langeveld CH, Pizao PE, van Rijswijk REN, Wagstaff J, Pinedo HM and Peters GJ: Effect of suramin on adenylate cyclase and protein kinase C. Anticancer Drug Des 9: 279-290, 1994.
27. Sosnowski J, Stetter-Neel C, Cole D, Durham JP and Mawhinney MG: Protein kinase C mediated antiproliferative glucocorticoid-sphinganine synergism in cultured Pollard III prostate tumor cells. J Urol 158: 269-274, 1997.
28. Powell CT, Gschwend JE, Fair WR, Brittis NJ, Stec D and Huryk R: Overexpression of protein kinase C-zeta (PKC-ζ) inhibits invasive and metastatic abilities of Dunning 3327 Mat-LyLu rat prostate cancer cells. Cancer Res 56: 4137-4141, 1996.
29. Lautier D, Canitrot Y, Deely RG and Cole SPC: Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 52: 967-977, 1996.
30. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJT, Juijn JA, Baas F and Borst P: Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1). in human cancer cell lines. Cancer Res 57: 3537-3547, 1997.
31. O'Brian CA, Ward NE, Gravitt KR and Fan D: Role of protein kinase C in multidrug resistance. Cancer Treat Res 73: 41-55, 1994.
32. Bergman PJ, Gravitt KR, Ward NE, Beitran P, Gupta KP and O'Brian CA: Potent induction of human colon cancer cell uptake of chemotherapeutic drags by N-mynstoylated protein kinase C-α (PKC-α) pseudosubstrate peptides through a P-glycoprotein-independent mechanism. Invest New Drugs (In press).
33. Dean NM, McKay R, Condon TP and Bennett CF: Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem 269: 16416-16424, 1994.
34. Levesque L, Dean NM, Sasmor H and Crooke ST: Antisense oligonucleotides targeting human protein kinase C-alpha inhibit phorbol ester induced reduction of bradykinin-evoked calcium mobilization in A549 cells. Mol Pharmacol 51: 209-216, 1997.
35. Dean N, McKay R, Miraglia L, Howard R, Cooper S, Giddings J, Nicklin P, Meister L, Ziel R, Geiger T, Muller M and Fabbro D: Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-α expression. Cancer Res 56: 3499-3507, 1996.
36. Yazaki T, Ahmad S, Chahlavi A, Zylber-Katz E, Dean NM, Rabkin SD, Martuza RL and Glazer RI: Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol Pharmacol 50: 236-242, 1996.
37. McGraw K, McKay R, Miraglia L, Boggs RT, Pribble JP, Muller M, Geiger T, Fabbro D and Dean NM: Antisense oligonucleotide inhibitors of isozymes of protein kinase C: In vitro and in vivo activity and clinical development as anti-cancer therapeutics. Anticancer Drug Des 12: 315-326, 1997.
38. Godson C, Bell KS and Insel PA: Inhibition of expression of protein kinase C-α by antisense cDNA inhibits phorbol estermediated arachidonate release. J Biol Chem 268: 11946-11950, 1993.
39. Rosson D, O'Brien TG, Kampherstein JA, Szallasi Z, Bogi K, Biumberg PM and Mullin JM: Protein kinase C-alpha activity modulates transepithelial permeability and cell junctions in the LLC-PK1 epithelial cell line. J Biol Chem 272: 14950-14953, 1997.
40. Uberall F, Giselbrecht S, Helbert K, Fresser F, Bauer B, Gschwendt M, Grunicke HH and Baier G: Conventional PKC-alpha, novel PKC-epsilon and PKC-theta, but not a typical PKC-lambda are MARCKS kinases in intact NIH3T3 fibroblasts. J Biol Chem 272: 4072-4078, 1997.